Here is a significant development which should not be underestimated.
Through the creation of the new pharmaceutical division BioProgress will be
able to apply its technologies to Dexo's products, develop new products and
market the enhanced products directly. This capability is expected to
demonstrate to consumers and partners the benefits of its technologies such as
XGEL.
At a guess this means that instead of selling, for example, a wafertab machine to a pharmaceutical company, BPRG can now produce and sell drugs (like biogenerics) for themselves.
The potential profits involved here are significant and show a very smart move by RT.
Bioprogress stock quotes
Bioprogress stock charts
Follow this thread
